Table 2 Demographic characteristics and common CVD risk factors of the participants
Variable | N=26 type 2 DM |
|---|---|
Age (years) | 60.8 ± 10.4 |
Sex, F (%) | 38.5% |
Height (m) | 1.7 ± .10 |
Weight (kg) | 92.4 ± 23 |
BMI (kg/m2) | 30.8 (29.1–36.7) |
Body fats % | 33.9 ± 6.8 |
Heart rate rest (bpm) | 71.4 ± 12.1 |
Resting SBP (mmHg) | 132 ± 15.7 |
Resting DBP (mmHg) | 80 ± 9.9 |
Total cholesterol (mmol/L) | 4.6 ± .96 |
Triglycerides (mmol/L) | 1.4 ± .56 |
HDL (mmol/L) | 1.2 ± .22 |
LDL (mmol/L) | 2.8 ± .93 |
HOMA | 2.3 (1.5–4.5) |
Ewing’s score | 2 (1.25–2.5) |
VO2peak (ml/kg/min) | 22.3 ± 4.5 |
Medications | |
Statins (%) | 46.2% |
Biguanides (%) | 53.8% |
ACE inhibitors (%) | 34.6% |
Ca channel blockers (%) | 7.7% |
Diuretics (%) | 7.7% |
Gliclazide (%) | 7.7% |
Fluoxetine (%) | 7.7% |
Alpha-blockers (%) | 3.8% |
Thyroxin (%) | 3.8% |
Rivaroxaban (%) | 3.8% |
Sitagliptin (%) | 3.8% |
NSAIDs (%) | 3.8% |
Beta-blockers (%) | 3.8% |